Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06293620 in Type 2 Diabetes Mellitus
NCT02211261Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Jan 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06293620 in type 2 diabetes mellitus (T2DM) (9 cohorts), sponsored by Pfizer. Primary endpoints: Adverse Events, Dose Limiting or Intolerable Adverse Events and 1 more. Started Sep 2014; status: completed.
02
Drugs
PF-06293620
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02211261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211261.